Man LM, Morris AL, Keng M. New therapeutic strategies in acute lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(3):197–206. https://doi.org/10.1007/s11899-017-0380-3.

Article  PubMed  Google Scholar 

Faderl S, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165–76. https://doi.org/10.1002/cncr.24862.

Article  CAS  PubMed  Google Scholar 

Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med. 2020;10(6):a034819. https://doi.org/10.1101/cshperspect.a034819.

Article  PubMed  PubMed Central  Google Scholar 

Worden FP, Khoriaty RN, Cooney KA, Deininger M. Hematology board review: blueprint study guide and Q & A. Demos Medical Publishing/Springer Publishing Company, 2018.

Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70. https://doi.org/10.1186/s13045-020-00905-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowe JM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–7. https://doi.org/10.1182/blood-2005-04-1623.

Article  CAS  PubMed  Google Scholar 

Marks DI, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136–45. https://doi.org/10.1182/blood-2009-08-231217.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeAngelo DJ, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330–42. https://doi.org/10.1200/EDBK_280175.

Article  PubMed  Google Scholar 

Larson RA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556–64.

CAS  PubMed  Google Scholar 

Kantarjian H, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–801. https://doi.org/10.1002/cncr.20668.

Article  CAS  PubMed  Google Scholar 

Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577–e577. https://doi.org/10.1038/bcj.2017.53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribera J-M, et al. Treatment of high-risk philadelphia chromosome–negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. JCO. 2014;32(15):1595–604. https://doi.org/10.1200/JCO.2013.52.2425.

Article  CAS  Google Scholar 

•• Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. https://doi.org/10.1056/NEJMoa1609783. Multi-institutional phase III trial which demonstrated that blinatumomab resulted in longer overall survival than chemotherapy among adult patients with relapsed or refractory B-ALL.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dombret H, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(9):2214–22. https://doi.org/10.1080/10428194.2019.1576872.

Article  CAS  PubMed  Google Scholar 

Short NJ, et al. Updated results of a phase II study of reduced-intensity chemotherapy with mini-hyper-CVD in combination with inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):823–823. https://doi.org/10.1182/blood-2019-125136.

Article  Google Scholar 

Advani AS, et al. Results of SWOG 1318: a phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):33–33. https://doi.org/10.1182/blood-2018-99-111992.

Article  Google Scholar 

Richard-Carpentier G, et al. Updated results from the phase II study of hyper-CVAD in sequential combination with blinatumomab in newly diagnosed adults with B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2019;134(Supplement_1):3807–3807. https://doi.org/10.1182/blood-2019-129657.

Article  Google Scholar 

• Advani AS, et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574–82. https://doi.org/10.1200/JCO.21.01766. Phase II trial that evaluated frontline use of blinatumomab followed by POMP maintenance in patients with Ph− B-ALL (ORR 66%, 1-year OS 56%, 3-year OS 37%).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jabbour E, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878–85. https://doi.org/10.1016/S2352-3026(22)00285-X.

Article  CAS  PubMed  Google Scholar 

• Foà R, et al. Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–23. https://doi.org/10.1056/NEJMoa2016272. Phase II trial that evaluated a chemotherapy-free combination of dasatinib and blinatumomab, which noted complete remission in 98% of patients and 18-month follow up OS of 95%.

Article  PubMed  Google Scholar 

• Jabbour E, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24–34. https://doi.org/10.1016/S2352-3026(22)00319-2. Phase II trial that evaluated a chemotherapy-free combination of ponatinib and blinatumomab, which resulted in a complete molecular response rate of 87% and a 1-year OS of 95% for patients with newly diagnosed Ph-positive ALL as well as a complete molecular response rate of 79% and a 1-year OS of 79% for patients with relapsed or refractory Ph-positive ALL.

Article  CAS  PubMed  Google Scholar 

“BLINCYTO (blinatumomab) [package insert].” Thousand Oaks, CA: Amgen Inc, 2018. Accessed: Feb. 21, 2023. [Online]. Available: https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf.

Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255–60. https://doi.org/10.1016/j.yexcr.2011.03.010.

Article  CAS  PubMed  Google Scholar 

“Blincyto: drug approval package.” United States Food and Drug Administration, 2015. Accessed: Feb. 21, 2023. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125557Orig1s007.pdf.

Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4. https://doi.org/10.1186/s40364-018-0116-0.

Article  PubMed  PubMed Central  Google Scholar 

Stein AS, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2(13):1522–31. https://doi.org/10.1182/bloodadvances.2018019034.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klinger M, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226–33. https://doi.org/10.1182/blood-2012-01-400515.

Article  CAS  PubMed  Google Scholar 

Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. https://doi.org/10.1016/S1470-2045(14)71170-2.

Article  CAS  PubMed  Google Scholar 

Martinelli G, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. JCO. 2017;35(16):1795–802. https://doi.org/10.1200/JCO.2016.69.3531.

Article  CAS  Google Scholar 

Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):567–72. https://doi.org/10.1182/asheducation-2016.1.567.

Article  PubMed  PubMed Central  Google Scholar 

Teachey DT, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–7. https://doi.org/10.1182/blood-2013-02-485623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benjamin JE, Stein AS. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3):142–56. https://doi.org/10.1177/2040620716640422.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334–42. https://doi.org/10.1016/j.pharmthera.2012.07.013.

Article  CAS  PubMed  Google Scholar 

Rogala B, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther. 2015;15(6):895–908. https://doi.org/10.1517/14712598.2015.1041912.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zugmaier G, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4(9):e244–e244. https://doi.org/10.1038/bcj.2014.64.